Michael E. Jones
YOU?
Author Swipe
View article: Addressing Synchrotron Challenges for CMB Observations: ELFS-SA Collaboration for Robust Foreground Removal
Addressing Synchrotron Challenges for CMB Observations: ELFS-SA Collaboration for Robust Foreground Removal Open
Upcoming cosmic microwave background (CMB) experiments aim to detect primordial gravitational waves with unprecedented sensitivity. Effective foreground removal is essential to avoid biases in the measurement of the tensor-to-scalar ratio …
View article: Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma Open
BRCA-associated homologous recombination deficiency (HRD) is present in ~ 50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA-…
View article: Inherited chromosomally integrated human herpesvirus 6: regional variation in prevalence, association with angina, and identification of ancestral viral lineages in two large UK studies
Inherited chromosomally integrated human herpesvirus 6: regional variation in prevalence, association with angina, and identification of ancestral viral lineages in two large UK studies Open
Tens of millions of people worldwide have inherited chromosomally integrated human herpesvirus 6 (iciHHV-6), yet we know little about the consequences. iciHHV-6-positive individuals inherit the genome of HHV-6A or HHV-6B in the germline, a…
View article: Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts Open
View article: Central and peripheral adiposity and premenopausal breast cancer risk: a pooled analysis of 440,179 women
Central and peripheral adiposity and premenopausal breast cancer risk: a pooled analysis of 440,179 women Open
Our analyses did not support an association between central adiposity and overall premenopausal breast cancer risk after adjustment for BMI. However, our findings suggest associations might differ by breast cancer hormone receptor and intr…
View article: Association between socioeconomic position and lung cancer incidence in 16 countries: a prospective cohort consortium study
Association between socioeconomic position and lung cancer incidence in 16 countries: a prospective cohort consortium study Open
View article: Seasonal variation in sunlight exposure is differently associated with changes in T regulatory and T-helper 17 cell blood counts in adolescent and adults females: a pilot study
Seasonal variation in sunlight exposure is differently associated with changes in T regulatory and T-helper 17 cell blood counts in adolescent and adults females: a pilot study Open
Higher prevalence of multiple sclerosis at higher latitudes is associated with reduced sunlight during childhood. Alterations in inflammatory Th17 and regulatory T cells (Treg) are associated with autoimmunity. In Hobart, Australia (latitu…
View article: The PS4-likelihood ratio calculator: flexible allocation of evidence weighting for case-control data in variant classification
The PS4-likelihood ratio calculator: flexible allocation of evidence weighting for case-control data in variant classification Open
Background The 2015 American College of Medical Genetics/Association of Molecular Pathology (ACMG/AMP) variant classification framework specifies that case-control observations can be scored as ‘strong’ evidence (PS4) towards pathogenicity…
View article: Supplementary Table S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S4. Differential gene expression analysis comparing transcriptomes of tumors based on BRCA and RB1 alteration status.
View article: Supplementary Table S17 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
View article: Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S10. Immune cell subsets inferred from gene expression data by combined homologous recombination deficiency and RB1 status.
View article: Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
View article: Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S3. Number of RNA-seq primary tumor samples by library type and alteration group.
View article: Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S9. Bars indicate the number of differentially expressed genes (Benjamini-Hochberg adjusted P value < 0.05) between HGSC tumors grouped by HRD and/or RB1 status as shown.
View article: Supplementary Table S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S8. Antibodies and reagents.
View article: Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Multivariate analysis of molecular alterations and OS in patients with HGSC and ENOC.
View article: Table 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Table 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Clinicopathologic characteristics and RB1 expression patterns across histotypes.
View article: Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S6. Mutational signatures in homologous recombination deficiency and RB1 subgroups.
View article: Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S1. Details of participating Ovarian Tumor Tissue Analysis (OTTA) consortium studies and ethics approvals.
View article: Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
View article: Supplementary Figure S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S4. HGSC cell lines with innate RB1 and/or BRCA1 alterations.
View article: Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S3. Overall survival by combined RB1 and p53 expression in ENOC, and RB1 protein expression and BRCA status in HGSC.
View article: Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S3. Overall survival by combined RB1 and p53 expression in ENOC, and RB1 protein expression and BRCA status in HGSC.
View article: Supplementary Figure S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S1. Patients and tumor samples analyzed in this study.
View article: Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S9. Bars indicate the number of differentially expressed genes (Benjamini-Hochberg adjusted P value < 0.05) between HGSC tumors grouped by HRD and/or RB1 status as shown.
View article: Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S3. Number of RNA-seq primary tumor samples by library type and alteration group.
View article: Supplementary Table S11 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S11 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S11. Multivariable adjusted association of molecular alterations and overall survival in HGSC and ENOC among patients with residual disease* status.
View article: Supplementary Table S16 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S16 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S16. Median survival according to germline BRCA1 and BRCA2 status by RB1 protein expression.
View article: Supplementary Table S19 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S19 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S19. Relative expression of BRCA1 and RB1 by qPCR in AOCS30 CRISPR knockout model.
View article: Supplementary Table S15 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S15 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S15. Clinical characteristics of patients with HGSC according to RB1 and BRCA status.